Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: A 4-year study

Rheumatology

Volumn 49, Issue 6, 2010, Pages 1107-1111

  Spadaro, Antonio ^a   Punzi, Leonardo ^b   Marchesoni, Antonio ^c   Lubrano, Ennio ^d   Mathieu, Alessandro ^e   Cantini, Fabrizio ^f   Olivieri, Ignazio ^g   Salvarani, Carlo ^h   Scarpa, Raffaele ⁱ   Scrivo, Rossana ^a   Ramonda, Roberta ^b   Porru, Giovanni ^c   D'Angelo, Salvatore ^g   Catanoso, Mariagrazia ^h   Atteno, Mariangela ⁱ   Valesini, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

^f MISERICORDIA E DOLCE HOSPITAL   (Italy)

^g SAN CARLO HOSPITAL   (Italy)

^h Reggio Emilia Hospital   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Ankylosing spondylitis; Anti TNF drugs; Psoriatic arthritis; Spondylarthropathies

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DRUG EFFICACY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SPONDYLOARTHRITIS; SPONDYLOARTHROPATHY; SURVIVAL; THROMBOPHLEBITIS; UVEITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLARTHRITIS; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953527617     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq008     Document Type: Article

References (23)

1. Kavanaugh A, Tutuncu Z, Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006;18:347-53.
2. Brocq O, Roux CH, Albert C et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007;74:148-54.
3. Braun J, Brandt J, Listing J et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
4. Nikas SN, Alamanos Y, Voulgari PV, Pliacou XI, Papadopoulos CG, Drosos AA. Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005;64:940-2.
5. Davis JC, Van der Hejde DM, Braun J et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64: 1557-62.
6. Davis JC Jr, van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67: 346-52.
7. Gomez-Reino JJ, Carmona L. BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
8. Coates LC, Cawkwell LS, Ng NW et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology 2008; 47:897-900.
9. Coates LC, Cawkwell LS, Ng NW et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008;67:717-9.
10. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
11. Bombardieri S, Ruiz AA, Fardellone P et al. Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191-9.
12. Haraoui B. Is there a rationale for switching from one antitumor necrosis factor agent to another? J Rheumatol 2004;31:1021-2.
13. Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
14. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
15. Salvarani C, Olivieri I, Pipitone N et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol 2006;24:70-8.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
17. Nikas SN, Voulgari PV, Alamanos Y et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006;65: 257-60.
18. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005; 34:353-8.
19. Iannone F, Trotta F, Montecucco C et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007;66: 249-52.
20. Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32: 2183-5.
21. Cantini F, Niccoli L, Benucci M et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55:812-6.
22. Conti F, Ceccarelli F, Marocchi E et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66: 1393-7.
23. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumor necrosis factor a antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology 2006; 45:1121-4.